This company has been acquired
CNCE Stock Overview
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Concert Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.37 |
| 52 Week High | US$8.55 |
| 52 Week Low | US$2.66 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | 92.86% |
| 1 Year Change | 203.26% |
| 3 Year Change | -9.22% |
| 5 Year Change | -64.31% |
| Change since IPO | -40.97% |
Recent News & Updates
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Shareholder Returns
| CNCE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | 1.0% | 1.2% |
| 1Y | 203.3% | 0.7% | 24.9% |
Return vs Industry: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
Return vs Market: CNCE exceeded the US Market which returned -5.5% over the past year.
Price Volatility
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNCE's share price has been volatile over the past 3 months.
Volatility Over Time: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company’s lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals.
Concert Pharmaceuticals, Inc. Fundamentals Summary
| CNCE fundamental statistics | |
|---|---|
| Market cap | US$520.71m |
| Earnings (TTM) | -US$126.68m |
| Revenue (TTM) | US$32.04m |
16.3x
P/S Ratio-4.1x
P/E RatioIs CNCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNCE income statement (TTM) | |
|---|---|
| Revenue | US$32.04m |
| Cost of Revenue | US$102.70m |
| Gross Profit | -US$70.66m |
| Other Expenses | US$56.02m |
| Earnings | -US$126.68m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | -220.53% |
| Net Profit Margin | -395.36% |
| Debt/Equity Ratio | 0% |
How did CNCE perform over the long term?
See historical performance and comparison